三元生物(301206) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 reached ¥138,076,442.87, an increase of 19.16% year-over-year, and year-to-date revenue totaled ¥514,923,140.19, up 46.62% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥29,093,416.24, a significant increase of 248.18% year-over-year, with year-to-date net profit at ¥81,007,173.94, up 94.39%[2] - Basic earnings per share for Q3 2024 was ¥0.14, reflecting a 250.00% increase year-over-year, while year-to-date earnings per share stood at ¥0.40, up 90.48%[2] - The total operating revenue for the current period is ¥514,923,140.19, an increase of 46.5% compared to ¥351,192,635.35 in the previous period[23] - The net profit attributable to the parent company's shareholders is ¥81,007,173.94, which is a 94.0% increase from ¥41,672,900.57 in the previous period[25] - Basic and diluted earnings per share for the current period are both ¥0.40, compared to ¥0.21 in the previous period[25] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥6,970,913.77 for the first nine months of 2024, a decrease of 68.23% compared to the same period last year[8] - The company’s cash flow from investing activities increased by 123.04% year-over-year, amounting to ¥58,019,291.88 for the first nine months of 2024[8] - Cash received from sales of goods and services is ¥532,393,814.21, an increase from ¥358,348,606.55 in the previous period, representing a 48.5% growth[26] - Operating cash inflow for Q3 2024 was CNY 585.67 million, up from CNY 421.27 million in Q3 2023, representing a 39% increase[27] - Cash inflow from investment activities totaled CNY 394.77 million, significantly higher than CNY 157.91 million in the same period last year[27] - The company received CNY 360 million from investment recoveries, a significant increase from CNY 150 million in Q3 2023[27] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥4,766,726,254.89, a decrease of 0.91% from the end of the previous year[2] - The company’s total liabilities decreased to ¥239,671,475.10 from ¥272,403,930.27, indicating a reduction of approximately 12.0%[22] - The company reported total current assets of 3,356,204,167.30 CNY as of September 30, 2024, compared to 321,813,853.97 CNY in the previous period[20] - The company’s fixed assets increased to 989,234,419.37 CNY from 883,575,315.67 CNY in the previous period[20] - The company’s accounts payable increased to 57,438,271.94 CNY from 46,239,949.13 CNY in the previous period[20] Shareholder Information - The company’s major shareholder, 聂在建, holds 46.23% of the shares, amounting to 93,537,770 shares[9] - The total number of shares held by the top 10 unrestricted shareholders is 56,000,000 shares, accounting for 27.5% of the total share capital[10] - The company reported a total of 92,946,000 restricted shares at the beginning of the period, with no shares released during the period[13] - The number of shares held by the shareholder Li Dechun increased by 720,000 shares, bringing the total to 2,880,000 shares[13] - The company has a total of 99,681,375 restricted shares at the end of the period, which includes 922,969 shares added during the period[13] - The company has not reported any changes in the top 10 shareholders due to securities lending or returning of shares[12] Governance and Operations - The company successfully completed the election of its fifth board of directors and supervisory board, ensuring continuity in governance[15] - The company has appointed Rongcheng Accounting Firm as its external auditor for the 2024 fiscal year, replacing Dahua Accounting Firm due to regulatory issues[18] - The company plans to increase its operating locations, specifically at 101 Wutong 10th Road, Binbei District, Binzhou City[17] Costs and Expenses - The company experienced a 32.24% increase in operating costs for the first nine months of 2024, totaling ¥461,905,205.46, primarily due to increased sales volume[7] - The total operating costs for the current period amount to ¥512,885,968.89, up from ¥395,084,253.43 in the previous period, reflecting a 29.7% increase[24] - Research and development expenses for the current period are ¥35,805,522.37, a slight decrease from ¥36,626,985.64 in the previous period[24]